Top 20: INDIA - Marginal growth

India registered a flat growth of 3 percent to clock $25.8 billion in revenue



Country Analysis for the APAC region show that India's bioscience success story received a jolt in 2013 due to regulatory and pricing issues.

The sector grew only by 3 percent. Interestingly, India too had eight companies that crossed the $1 billion mark. In fact, India's two leading companies Sun Pharma and Dr Reddy's have touched the $2 billion mark for the first time.

India announced its plan to elevate its pharma industry to touch $100 billion by 2020.

USFDA deputed training personnel to Indian state, Gujarat, to enhance quality standards of drugs exported from the state.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email